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Abstract Chemoradiation (CRT) is a valuable treatment
option for advanced hypopharyngeal squamous cell cancer
(HSCC). However, long-term toxicity and quality of life
(QOL) is scarcely reported. Therefore, eYcacy, acute and
long-term toxic eVects, and long-term QOL of CRT for
advanced HSCC were evaluated,using retrospective study
and post-treatment quality of life questionnaires. in a
tertiary hospital setting. Analysis was performed of 73
patients that had been treated with CRT. Toxicity was rated
using the CTCAE score list. QOL questionnaires EORTC
QLQ-C30, QLQ-H&N35, and VHI were analyzed. The
most common acute toxic eVects were dysphagia and
mucositis. Dysphagia and xerostomia remained problematic
during long-term follow-up. After 3 years, the disease-
speciWc survival was 41%, local disease control was 71%,
and regional disease control was 97%. The results indicated
that CRT for advanced HSCC is associated with high loco-
regional control and disease-speciWc survival. However,
signiWcant acute and long-term toxic eVects occur, and
organ preservation appears not necessarily equivalent to
preservation of function and better QOL.
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Introduction
For many years, surgical resection followed by radiotherapy
has been the standard treatment for advanced hypopharyn-
geal squamous cell carcinoma (HSCC) [1, 2]. However,
since the early 1990s, chemoradiation (CRT) has become a
valuable alternative treatment option [3, 4]. Due to organ
preservation, it has been suggested that CRT is followed by
a better long-term quality of life (QOL) than after total
laryngectomy (TLE), with similar survival [3, 4].
Two strategies have been developed during the past
decade: sequential (i.e., induction) chemotherapy followed
by radiotherapy, and concurrent CRT. Superior results of
concurrent administration compared with sequential CRT
have been reported regarding locoregional control, disease-
free survival, and overall survival rates in case of laryngeal
cancer [5]. No randomized studies on this subject for
HSCC have been performed. However, the meta-analysis
of Pignon et al. [6] suggests that concomitant CRT in case
of HSCC leads to improved survival compared with radio-
therapy alone.
Boscolo-Rizzo et al. [7] described better QOL after CRT
compared with TLE. On the other hand, several other studies
reported similar QOL outcomes between these modalities
[8,  9]. Moreover, growing evidence is pointing towards
severe acute and long-term toxicity rates related to CRT,
indicating that organ preservation is not necessarily equiva-
lent to preservation of function and better QOL [10, 11].
In summary, a clear picture concerning long-term toxicity
and QOL after CRT for head and neck cancer has not
evolved yet. Hence, the best treatment modality to cure the
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cancer while minimizing adverse eVects and toxicity in
these patients remains subject to debate. Detailed reports of
CRT speciWcally addressing HSCC are particularly scarce.
The objectives of this study are to evaluate the eYcacy,
acute and long-term toxic eVects, and long-term QOL of
concurrent CRT as a primary treatment modality for
advanced HSCC.
Methods
A total of 73 consecutive patients who received concurrent
CRT for stage III-IV primary HSCC between January 2000
and January 2008 were included in this study. The study
was approved by the institutional ethical review board of
the Rotterdam Erasmus Medical Center. Medical records
were reviewed for patient demographics, tumor site and
stage, treatment, morbidity during and after treatment, and
follow-up. Comorbidity was assessed using the Adult
Comorbidity Evaluation 27 Index (ACE-27) [12].
All patients received radiotherapy, concurrent with che-
motherapy starting on day 1 of radiotherapy. Radiotherapy
was given for 43 days (median, range: 17–47 days). The
radiation  Weld encompassed the gross disease (primary
tumor and/or nodal disease) with a 0.5 cm margin. In all
patients, either 3-dimensional conformal (3DCRT) or “step
and shot” intensity-modulated radiotherapy (IMRT) tech-
niques were applied. Usually, 5–11 non-opposing, coplanar
beams were chosen to ensure that at least 95% of the dose
encompassed the target volume. Patients were completely
treated according to an accelerated fractionation schedule.
The intended radiation dose was 70 Gray (Gy) in 35 frac-
tions of 2 Gy, given six times a week. The cumulative dose
to the spinal cord was not to exceed 50 Gy. In those patients
in whom parotid and submandibular glands sparing was
feasible, the mean dose to at least one parotid gland was
kept below 26 Gy. The mean dose to submandibular gland
was kept below 39 Gy, when possible. Surface bolus was
used for nodal disease with skin invasion or fungation. The
chemotherapeutic regimen was two cycles of cisplatin
100 mg/m2 on day 1 and 22 of the treatment for the major-
ity of the patients (77%). Eleven percent of the patients
received four cycles of paclitaxel 60 mg/m2 once a week,
and 8% received diVerent chemotherapeutics due to a
cardiovascular risk proWle. In three patients (4%) 5FU/
carboplatin instead of cisplatin was given due to pre-existent
perceptive hearing loss.
Toxicity and morbidity were evaluated during treatment,
as well as 3, 6, 12, and 24 months after treatment, using the
Common Terminology Criteria for Adverse Events, version
3.0 (CTCAE) [13]. In addition, weight loss, mode and dura-
tion of nutritional support, and renal function were evalu-
ated before, during, and after treatment. EYcacy data
included assessment of residual disease (deWned as residual
or new tumor within 3 months after the end of treatment)
recurrent disease, disease-free survival and overall survival.
The Quality of Life Questionnaires EORTC QLQ-C30
(general cancer questionnaire, version 3.0) [14] and QLQ-
H&N35 (speciWc Head and Neck module) [15] were sent to
all patients that were alive at the time of analysis. In addi-
tion, the Voice Handicap Index (VHI) [16] was used to
evaluate the psychosocial consequences of voice disorders.
Statistical analysis was performed using SPSS 16.0. Paired
data were analyzed using the paired t test. Non-parametric
tests were performed using the Wilcoxon signed rank test
and diVerences between percentages were calculated using
Table 1 Patient demographics, co-morbidity, intoxications and tumor
characteristics
Characteristic Value (%)
Total patients 73 (100)
Gender
Men 61 (84)
Women 12 (16)
Age (years)
Median 56
Range 43–78
ACE-classiWcation
Grade 0 38 (52)
Grade 1 22 (30)
Grade 2 12 (17)
Grade 3 1 (1)
Weight loss before start 
of therapy (%)
Grade 0: <5 43 (59)
Grade 1: 5–9 17 (23)
Grade 2: 10¡20 10 (14)
Grade 3: >20 3 (4)
Smoking (cigarettes/day)
<10 16 (22)
10–25 21 (29)
>25 36 (49)
Alcohol (units/day)
<6 34 (47)
6–10 32 (44)
>10 7 (9)
Tumor site
Piriform sinus 60 (82)
Overlapping region 5 (7)
Posterior wall 4 (5.5)
Remaining 4 (5.5)
TNM stage
III 11 (15)
IV 62 (85)Eur Arch Otorhinolaryngol (2012) 269:939–946 941
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the Chi-square test. Survival was calculated with the
Kaplan–Meier method.
Results
Patient demographics, primary tumor site, and disease stage
Patient demographics, comorbidity, intoxications, and
tumor characteristics are shown in Table 1. The ACE-
classiWcation was mainly determined by cardiovascular risk
proWle (37%), substance abuse (20%), and previous malig-
nancies (14%). Prior to the start of therapy, 18% of the
patients had lost more than 10% of their original body
weight.
Acute toxicity
Three patients died during the treatment as a result of a
myocardial infarction, pneumonia in a patient with severe
chronic obstructive pulmonary disease, or sepsis thought to
be the result of ulceration of the HSCC (2 days after the
start of CRT, not related to the treatment), resulting in an
overall mortality rate of 4% and a treatment-related mortality
rate of 3%.
Treatment was completed according to protocol in 91% of
the patients. Three previously mentioned patients (4%) died
during treatment. In another 4% of the patients, the second
chemotherapeutic cycle was postponed by 1 week due to
renal insuYciency (n = 2) or pneumonia (n = 1). One patient
(1%) received only one cycle of chemotherapy, due to an
intermittent myocardial infarction. Unscheduled admissions
during treatment were necessary in 27 patients (37%), mostly
due to infection (15 patients) or dehydration (8 patients).
Prior to treatment, 36% of the patients had a serum creat-
inine level below normal (<65 mol/L); the remaining 64%
had values within normal limits. During treatment, the
serum creatinine level increased from a mean of 67 mol/L
to 91 mol/L (p < 0.000). Overall, 22% of the patients had
>50% increase of the creatinine levels during treatment
(13% had >100% increase).
All graded 3 or 4 adverse events that were monitored
during treatment and after 3 and 6 months are displayed in
Table 2. Dysphagia was the most severe acute and long-
term adverse event that was reported. In 22% of the
patients, nutritional support was maintained by either
percutaneous gastrostomy (PRG) (n = 10) or nasogastric
(n = 6) tube feeding prior to or at the start of the treatment
due to severe weight loss, no standard prophylactic PRG or
feeding tube placement was performed. During and after
treatment, an additional 56% of the patients required PRG
(n = 34) or nasogastric (n = 7) tube feeding due to dysphagia
resulting in weight loss or dehydration. Nevertheless,
during treatment, 45% of the patients lost 5–9% of their
body weight (grade 1), and an additional 33% lost more
than 10% (grade 2 or 3).
Long-term toxicity
During the Wrst 3 months after therapy, 21 patients (30%)
were admitted due to complications: dehydration (33.3%),
intestinal infection (19%), dysphagia due to stenosis (19%),
pneumonia (14.3%), or other complications (14.3%).
Patients with stenosis presented with swallowing diYcul-
ties and were diagnosed on panendoscopy to exclude tumor
recurrence. Between the fourth and second year after the
treatment, most patients were admitted because of pharyn-
geal stenosis.
Table 2 Percentage grade 3 and 4 acute toxicity
Adverse event During treatment (%) After 3 months (%) After 6 months (%)
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Dysphagia 53 9 37 3 26 3
Mucositis 38 4 7 0 1 0
Pain 27 6 11 0 16 0
Skin toxicity 31 5 8 2 2 0
Fatigue 9 0 5 0 6 0
N a u s e a 6 3 22 00
Vomiting 5 2 2 0 0 0
Dyspnea 5 2 0 0 0 0
Dry mouth 6 0 14 0 10 2
Ototoxicity 6 0 3 0 0 0942 Eur Arch Otorhinolaryngol (2012) 269:939–946
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Overall performance was recorded with the Karnofsky
index during treatment and follow-up, as illustrated in
Fig. 1a. SigniWcant increase of this score post-treatment
(mean 87) compared with during treatment (mean 79) was
seen after 12 months (p =0 . 0 0 2 ) .
The percentage of graded 3 or 4 toxicity scores per
adverse event are presented in Table 2. Although mucositis
recovered mostly during the 6 months after treatment,
long-term dysphagia remained signiWcant. Six months
after treatment, 26 and 3% still had grade 3 and 4 dyspha-
gia, respectively (Fig. 1b). Despite tube feeding in 78% of
the patients during and after treatment, 22% of the
patients lost an additional 5–9% of their weight (grade 1),
and 5% of the patients lost more than 10% (grade 2 or 3)
in the Wrst months following treatment. Overall, most
acute toxicity resolved within a 3 months period. How-
ever, complaints of a grade 3 or 4 dry mouth increased.
After 6 months, 16% of the patients still experienced
grade 3 pain, but the mean CTC pain scores reduced to a
0.6 (grade 1) during the complete follow-up period
(p = 0.005, Fig. 1c).
Residual disease, disease recurrence and survival
During follow-up, recurrent or residual disease was
detected by means of MRI/CT-scan (58%), panendoscopy
(35%), or physical evaluation (7%). Residual disease, (i.e.,
tumor recurrence within 3 months after therapy) was found
in 16 patients (23%) of which three patients had local dis-
ease, resulting in a local disease control of 96% (67/70
patients) after 3 months. Eighty-one percent of patients
with residual disease had regional metastasis (13 patients)
conWrmed by ultrasound-guided FNA, of which 11 patients
were treated with salvage neck dissection. Hence, the
regional disease control after 3 months including salvage
surgery was 97% (68/70 patients).
In the period following the Wrst 3 months after therapy,
28 patients developed tumor recurrence. The mean time
between the end of therapy and recurrence of disease was
14 months (range 3–54 months). Of these patients, 17
patients had local, locoregional, or local and distant disease,
resulting in a local disease control of 71% at a mean follow-up
of 3 years. The Kaplan–Meier-Estimated cumulative 3-year
Fig. 1 Toxicity scores and survival during treatment and follow-up.
The mean scores and 95% conWdence interval (CI) of the Karnofsky
score (a), dysphagia score (b), and pain score (c) are displayed. Overall
cumulative survival (months) is shown in (d). Cum survival is
cumulative survivalEur Arch Otorhinolaryngol (2012) 269:939–946 943
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survival corrected for tumor recurrence or residual disease
was 42.1% (SD 6.1%).
Other patients with local recurrence were inoperable due
to tumor extension, comorbidity, or distant metastasis. In
addition, because three patients had regional recurrence of
their disease in this period, the regional disease control
after CRT and salvage neck dissection after 3 years was
93%. Furthermore, distant metastasis developed in nine
patients, of which most patients (70%) had pulmonary
metastasis. Other locations included costal, liver, or skin
metastasis. A second primary tumor was found in the
esophagus (n = 2) or lungs (n =1 ) .
The Kaplan–Meier curve for overall survival is shown
in Fig. 1d. The median overall survival (calculated
starting from the end of treatment) was 33 months (range
0–112 months). The 2 and 3-year survival rates were 56
and 38%, respectively. The disease-speciWc survival after
3 years was 41%.
Quality of life
The questionnaires were sent to all 24 patients who were
alive at the time of the study. Twenty patients returned the
completed questionnaires, resulting in a response rate of
83%. These patients were at least 2.5 years after treatment,
with a mean of 5 years. The mean overall score for the
Voice Handicap Index scale was 30.8 [§25.4 standard
deviation (SD)], which is deWned as mild-to-moderate
voice handicap. The individual subscale scores revealed a
mean (§SD; scale) functional score of 11.3 (9.8; mild-
to-moderate), a physical score of 12.7 (9.9; mild), and an
emotional score of 6.8 (7.2; mild). The results of the question-
naires are shown in Tables 3, 4, 5.
Discussion
A total of 73 patients were treated with concurrent CRT.
Three months after the treatment, local disease control was
96%, which gradually decreased to 71%, 3 years after the
end of the treatment. In addition, regional control was very
satisfying and durable, being 97 and 93% after 3 months
and 3 years, respectively. This is comparable with most
literature. HSCC consistently shows a trend for worse
survival compared to laryngeal carcinoma [6, 17]. Unfortu-
nately, most studies combine both groups in their analysis,
making a comparison more diYcult. In general, disease
speciWc survival after 3 years of 41% is comparable with
the literature [17–19].
Although synergy between chemotherapy and radiother-
apy enhances the eYcacy of the treatment [4–6], CRT is
associated with high morbidity during treatment. Urba et al.
[19] reported 79% of patients with any grade 3 or 4 toxicity
treated with CRT for carcinoma in the hypopharynx or base
of tongue. The signiWcant treatment-related toxicity is also
illustrated by 37% unscheduled admissions during treatment
Table 3 Quality of life questionnaire QLQ C-30
a Higher scores correspond with higher quality
b Higher scores correspond with higher severity of symptoms
Item Mean score
Global health statusa
Global health status 67
Functional scalesa
Physical functioning 75
Role functioning 55
Emotional functioning 73
Cognitive functioning 75
Social functioning 68
Symptom scalesb
Fatigue 40
Nausea and vomiting 48
Pain 22
Dyspnoea 25
Insomnia 14
Appetite loss 33
Constipation 11
Diarrhea 5
Financial diYculties 16
Table 4 Quality of life questionnaire QLQ H&N35
Higher scores correspond with higher severity of symptoms
Item Mean score
Symptom scales
Pain 16
Swallowing 34
Senses problems 34
Speech problems 31
Trouble with social eating 36
Trouble with social contact 14
Less sexuality 26
Teeth 26
Opening mouth 26
Dry mouth 39
Sticky saliva 51
Coughing 30
Felt ill 18
Pain killers 37
Nutritional supplements 47
Feeding tube 11
Weight loss 47
Weight gain 11944 Eur Arch Otorhinolaryngol (2012) 269:939–946
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in our study. Even higher numbers have been described in
other studies [17, 19], but this will in part be inXuenced by
hospital policy and logistical issues. Nevertheless, this
underlines the need for frequent patient monitoring during
treatment and the early post-treatment period.
Overall, most moderate to severe toxic eVects that
occurred during treatment disappeared during the early
post-treatment period. Mucositis is one of the most abun-
dant acute toxic eVects of CRT, and the 42% grade 3 or 4
rates in our study are comparable with most literature [17, 20].
As a result, tube feeding was required in 78% of the
patients during treatment. Nevertheless, after 1 year, 12%
of the patients still lost 5–9% of their body weight. This
eVect has previously been described by Hanna et al. [17]
who reported weight loss of 5.4 kg after 1 year in patients
with tube feeding, compared with 6.8 kg in patients without
tube feeding.
Prior to treatment, 18% of the patients had already lost
more than 10% of their original body weight. It has been
shown that prophylactic gastrostomy tube placement could
prevent weight loss and improve general condition during
therapy [21]. However, it was also associated with signiW-
cantly higher rates of late esophageal stricture formation
and in some cases mortality. Corry et al. [22] compared the
use of percutaneous endoscopic gastrostomy (PEG) tubes
versus nasogastric tubes for enteral feeding during CRT.
They concluded that the use of PEG tubes should be selec-
tive, because although PEG patients sustained signiWcantly
less weight loss at 6 weeks post-treatment, PEG tubes were
also associated with frequent infections, higher overall
costs, and more grade 3 dysphagia after 6 months than
nasogastric tube patients.
In our population, 13% of the patients had a 100% creat-
inine level increase as a result of the toxic chemotherapeutic.
Others have reported levels above normal limit up to 50%
[20], stressing the need for close monitoring of renal func-
tion during CRT with cisplatin.
Most studies describe a mean Karnofsky score as inclu-
sion criterion for treatment [9, 23]. In this study, the severity
of acute and long-term toxic eVects could also be illustrated
by a decrease in Karnofsky score during treatment and pro-
longed recovery during the follow-up period. The mean
Karnofsky score signiWcantly recovered after 1 year
(Fig. 1a), which is in line with other reports of long-term
toxicity of CRT for advanced head and neck cancer [24,
25]. The mean score did not further increase after 2 years
despite tumor control, which may be explained by new
comorbidity or long-term toxicity. Long-term toxicity of
CRT mainly consists of dry mouth and dysphagia [24, 25],
which was conWrmed by the QOL questionnaires, reporting
functional scores of 39 and 34 for dry mouth and swallow-
ing, respectively (Table 4). Although these are high num-
bers, similar rates have been described in other studies
[8, 11, 17, 20]. Dyspgahia and xerostomia are serious com-
plications of CRT resulting in medical, nutritional, and psy-
chological problems and social distress [25]. They have a
negative impact on the QOL of these patients due to associ-
ated diYculties in speech, chewing, swallowing, and poten-
tially severe dental decay, especially in patients treated for
laryngeal or hypopharyngeal lesions [25]. It has been
reported that the amount of dysphagia has a signiWcant
correlation with the degree of xerostomia [26].
Forty-eight percent of our patient population had ACE
score 1-3, indicating mild to severe comorbidity. Although
this will most likely have inXuenced the complication and
toxicity rates, the patient population was too diverse for
univariate analysis, due to small group sizes.
Hanna et al. [8] reported QOL results using the EORTC
QLQ-C30 and QLQ-H&N35 of 19 patients that were
treated with CRT for stage III–IV laryngeal cancer
15 months (average) prior to evaluation. Although the
patients in the current study were on average 5 years after
treatment, overall, the results of our study are similar or
slightly better (Tables 3,  4). However, some interesting
diVerences can be noted. In our study, less pain is reported,
combined with higher use of painkillers (Fig. 1c). This may
imply better pain control, but may also be due to lower
numbers of neck dissections, which has been reported to be
associated with arm and shoulder pain in 26% of the
patients 2 years after surgery [11,  27]. Furthermore, less
need for tube feeding is reported in the current study which
corresponds with better swallowing function.
On the other hand, Boscolo-Rizzo et al. [7] reported
superior results on virtually all categories of QOL-analysis
in 28 patients that had been treated with CRT 24 months
prior to evaluation. This indicates that large diVerences
between QOL studies still exist, which is most likely
explained by small group sizes. Nguyen et al. [11] per-
formed a meta-analysis comparing Wve QOL studies of
patients treated with CRT and concluded that dry mouth
(70%) and dysphagia (50%) were the most common long-
term side eVects. However, these studies described results
of diVerent QOL questionnaires, making comparison
between them diYcult. Furthermore, the VHI results reXect
mild or mild-to-moderate problems with speech rehabilita-
tion in most patients. To our knowledge, no VHI results
after CRT for HSCC have been reported previously.
Table 5 Voice handicap index (VHI) score
Overall VHI score No. of patients (%)
Mild (0–30) 10 (50)
Moderate (31–60) 8 (40)
Severe (61–120) 2 (10)Eur Arch Otorhinolaryngol (2012) 269:939–946 945
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However, our results compare favorably to VHI results of
patients 10 years after they had been treated with TLE [28].
The limitations of our retrospective series of CRT for
advanced HSCC are inherent to all retrospective clinical
study designs. These include, but are not limited to, selec-
tion bias of patients alive at time of the study and heterogeneity
of patients. In addition, baseline QOL status prior to ther-
apy is not reported, impeding conclusions on post-treatment
QOL outcome. Due to these limitations, combined with the
variable reported outcomes in the literature, we fully
endorse eVorts towards larger prospective clinical QOL tri-
als reporting the use of standardized questionnaires, which
would require a multi-center setting.
Future directions of CRT for advanced HSCC are point-
ing towards the use of new combinations of current thera-
peutic modalities. New strategies are being developed and
tested, including postoperative CRT [29], induction chemo-
therapy followed by CRT [30], and peroperative gene ther-
apy followed by CRT [31]. However, except from survival
and local disease control, focus must also remain on
reducing treatment-related toxicity and thereby improving
acute and long-term QOL.
Conclusion
Chemoradiation as a primary treatment option for advanced
HSCC is associated with high rates of local disease control
and disease-speciWc survival. However, signiWcant acute
and long-term toxic eVects occur, and organ preservation
appears not necessarily equivalent to preservation of
function. These eVects have a long-lasting repercussion on
the quality of life.
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